Sector News

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

December 3, 2022
Life sciences

As the corporate world evolves in the wake of COVID-19, Sanofi has christened an innovative headquarters to help keep pace.

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

The facility is designed around “new hybrid ways of working” and boasts an emphasis on energy efficiency. At the new site, each employee’s carbon footprint there is reduced by nearly 100% compared with Sanofi’s previous HQ.

Sanofi’s French roots are reflected in the building’s architecture, which boasts “original Eiffel pillars, witnesses of the pioneering spirit of Paris in the 1900s,” according to the company.

The building is crowned by a rooftop terrace all staff members can visit. Overall, the HQ is designed to be “as welcoming as ‘a home,’” Sanofi continued.

Sanofi snared a lease for the Paris property from private investor Ardian almost two years ago exactly in November 2020. With plans to make the reworked buildings its new headquarters, Sanofi at the time said it aimed to extend a “state-of-the-art working environment” to all its employees by 2022.

“This choice confirms Sanofi’s commitment to meeting its employees’ changing needs and expectations,” the company previously said.

Meanwhile, the COVID-19 pandemic introduced new digital modes of working around the globe, and Sanofi is keeping those shifts in mind by deploying video conferencing technologies and more throughout the new site.

Many other Big Pharma companies, such as GSK, have tweaked their offices to accommodate changes in work behaviors.

The Sanofi facility’s opening is joined by the launch of a companion phone app employees can use to manage their entire day. The app keeps track of employees’ remote workdays or arrival on site. It also helps manage locker access, offers the ability to book rooms or catering services and alerts users to events at the headquarters.

La Maison Sanofi represents a big leap in the company’s global push to modernize its workspaces around the world. In its release, Sanofi highlighted other new sites that embody the “same spirit” in Cambridge Crossing near Boston plus other French sites in Paris and Lyon.

It was only in July, in fact, that Sanofi cut the ribbon at its biggest U.S. site in Cambridge, Massachusetts. Sanofi has said it aims to boost collaboration between its research and development, medical and specialty care business units, among others, at the sprawling East Coast campus.

Sanofi is charting upgrades across its manufacturing operations, too. Of note, the company is building out two so-called Evolutive Vaccine Facilities (EVFs) in France and Singapore, which it had bolstered with investments in the vicinity of 900 million euros back in April.

Taking a closer look at the Singapore EVF, Sanofi has described the upcoming plant as “first-of-its-kind,” sporting fully digitalized and modular vaccine production capable of cranking out shots for Asia on a major scale. Sanofi envisions its vaccine modules will be able to crank out up to four vaccines at once regardless of the technology used, whether that be protein, mRNA or some other platform, the company has said.

By Fraiser Kansteiner


comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach